About
Revolutionizing Liquid Biopsy
MetaSight develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test – applicable for population scale screening.
Its approach leverages the world’s largest clinico multi-OMICS database, generated using our proprietary unbiased metabolomics, lipidomics, and proteomics platform.
Identity
| Name | MetaSight Diagnostics |
|---|---|
| Slug | metasight-diagnostics |
| Type / kind | startup |
| Source _id | XmKbIh1CTGkD6cPXHxAbkDH4UFV3reK2oRVNJH7ehnfRqbQcX443ye |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by Guardant Health on Feb 2026 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Rehovot |
| HQ address | Haim Holtsman St, Rehovot, Israel |
Web & social
| Website | https://metasightdx.com |
|---|---|
| https://www.linkedin.com/company/82976943 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
spectroscopyoncologydiagnosticspharmaceuticalsbiopsybiotechnologyinflammatory-diseasesblood-testbiomarkers
Funding
| Total raised | $8.0M |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}